跳至主要内容
临床试验/EUCTR2019-001633-14-IT
EUCTR2019-001633-14-IT进行中(未招募)1 期

A single-centre, open-label pilot study to assess the efficacy and safety of CBD oral solution as an adjunctive treatment for pediatric subjects with Developmental and Epileptic Encephalopathy - CBD_DEE

IRCCS, OSPEDALE PEDIATRICO BAMBINO GESÙ DI ROMA0 个研究点目标入组 20 人开始时间: 2021年5月24日最近更新:
适应症
相关药物

试验速览

阶段
1 期
状态
进行中(未招募)
发起方
入组人数
20

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional clinical trial of medicinal product

入排标准

性别
All

入选标准

  • oMale or female;
  • oAged between 2 and 7 years;
  • oA documented history of DEE [7];
  • oCurrently taking at least 1 other AED between one and four AEDs, with a stable antiseizure treatment for the previous 4 weeks (including ketogenic diet and vagus nerve stimulation);
  • oInadequately seizure control with 2 or more current or prior AEDs;
  • oWritten informed consent provided by the participant and/or parent(s)/caregiver(s).
  • Are the trial subjects under 18? yes
  • Number of subjects for this age range:
  • F.1.2 Adults (18-64 years) no
  • F.1.2.1 Number of subjects for this age range
  • F.1.3 Elderly (>=65 years) no
  • F.1.3.1 Number of subjects for this age range

排除标准

  • oClinically significant unstable medical or psychiatric conditions that may place patient’s safety at risk;
  • oClinically significant liver disease or serum aminotransferase (ALT or AST) >3 times the upper limit of the normal range or total bilirubin >2 times the upper limit of the normal range or international normalized ratio (INR) >1.5;
  • oKnown or suspected intolerance or hypersensitivity to cannabinoids or any of the excipients of the medicinal product such as sesame oil;
  • oCurrent use of ACTH or other systemic steroids;
  • oCurrent use (or use in the previous 2 months) of medicinal cannabis, or synthetic cannabinoid-based medications;
  • oInadequate supervision by parent(s)/caregiver(s) in the judgment of investigators
  • oStable felbamate dosing = 1 year;
  • oSubjects who have been part of a clinical trial involving another investigational product in the previous six months;
  • oSubjects with severe renal impairment: estimated glomerular filtration rate (eGFR) calculated as crCL < 30 ml/min, according to Schwartz equation.

研究者

发起方
IRCCS, OSPEDALE PEDIATRICO BAMBINO GESÙ DI ROMA

相似试验

撤回
1 期
A SINGLE CENTER OPEN-LABEL PILOT STUDY TO EVALUATE THE TOLERABILITY AND SAFETY OF A SYNTHETIC SOFT TISSUE IMPLANT MATERIAL IN THE SKIN OF NORMAL VOLUNTEERSTolerability and safety of a new synthetic soft tissue implant material for soft tissue augmentation in healthy volunteers.Surgery - Other surgery
ACTRN12607000223437COSMETREND PTY LTD8
已完成
1 期
A single center, open-labeled, pilot study to evaluate the safety and efficacy of cardiac cycle-synchronized electrical lower limb muscle stimulation therapy for cardiovascular diseaseatent heart failure (NYHA class: II-III), ischemic heart disease (CCS class: II-III), peripheral artery disease (Fontaine class: II-IV), pulmonary artery hypertension (WHO class: II-III), and healthy adult
JPRN-UMIN000026841Kurume University School of Medicine, Division of Cardiovascular Medicine, Department of Internal Medicine30
招募中
1 期
Pentosan Polysulfate Sodium (PPS) in subjects with mucopolysaccharidosis type I (MPS I)Mucopolysaccharidosis type I (MPS I)Metabolic and Endocrine - Metabolic disordersHuman Genetics and Inherited Disorders - Other human genetics and inherited disorders
ACTRN12620000823976Paradigm Biopharmaceuticals Pty Ltd10
尚未招募
1 期
Biocompatible & Biodegradable Polymeric Skin Grafts for Wounds
CTRI/2020/11/029284SASTRA Deemed University
招募中
1 期
A pilot single center, open label trial to assess the impact of doxycycline postexposure prophylaxis on antimicrobial resistance (SafeDoxyPEP trial)Bacterial sexually transmittable diseases (chlamydia, gonorrhea, syphilis)
CTIS2023-507137-24-00Institute Of Tropical Medicine78
A pilot study to assess the efficacy and safety of... | 临床试验